Tags

Type your tag names separated by a space and hit enter

Ivermectin: A Closer Look at a Potential Remedy.
Cureus. 2020 Sep 11; 12(9):e10378.C

Abstract

Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the search for effective treatment and vaccines has been exponentially on the rise. Finding effective treatment has been the core of attention of many scientific reports and antivirals are in the center of those treatments. Numerous antivirals are being studied for the management of the coronavirus disease 2019 (COVID-19) pneumonia caused by the SARS-CoV-2. Remdesivir was the first drug to gain emergency FDA approval to be used in COVID-19. Similarly, favipiravir, an anti-influenza drug, is being studied as a potential agent against COVID-19. Contrastingly, hydroxychloroquine has been a controversial drug in the management of COVID-19. Nevertheless, the National Institute of Health (NIH), along with the World Health Organization (WHO), have discontinued clinical trials for hydroxychloroquine as the drug showed little or no survival benefit. Ivermectin, an antihelminthic drug, has shown antiviral properties previously. Additionally, it was described to be effective in vivo against the SARS-CoV-2. However, its survival benefit in patients with COVID-19 has not been documented. We herein propose the theory of inhaled ivermectin which can attain the desired lung concentration that will render it effective against SARS-CoV-2.

Links

PMC Free PDF

Authors+Show Affiliations

Elkholy KO
Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.
Hegazy O
Internal Medicine, Mercy Hospital, Chicago, USA.
Erdinc B
Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.
Abowali H
Internal Medicine, Brookdale University Hospital Medical Center, Brooklyn, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33062500

Citation

Elkholy, Karim O., et al. "Ivermectin: a Closer Look at a Potential Remedy." Cureus, vol. 12, no. 9, 2020, pp. e10378.
Elkholy KO, Hegazy O, Erdinc B, et al. Ivermectin: A Closer Look at a Potential Remedy. Cureus. 2020;12(9):e10378.
Elkholy, K. O., Hegazy, O., Erdinc, B., & Abowali, H. (2020). Ivermectin: A Closer Look at a Potential Remedy. Cureus, 12(9), e10378. https://doi.org/10.7759/cureus.10378
Elkholy KO, et al. Ivermectin: a Closer Look at a Potential Remedy. Cureus. 2020 Sep 11;12(9):e10378. PubMed PMID: 33062500.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ivermectin: A Closer Look at a Potential Remedy. AU - Elkholy,Karim O, AU - Hegazy,Omar, AU - Erdinc,Burak, AU - Abowali,Hesham, Y1 - 2020/09/11/ PY - 2020/10/16/entrez PY - 2020/10/17/pubmed PY - 2020/10/17/medline KW - antiviral therapy KW - coronavirus 2019 (covid-19) KW - favipiravir KW - hydroxychloroquine KW - inhaled antivirals KW - ivermectin KW - remedisivir KW - severe acute respiratory syndrome coronavirus 2 (sars-cov-2) SP - e10378 EP - e10378 JF - Cureus JO - Cureus VL - 12 IS - 9 N2 - Amid the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the search for effective treatment and vaccines has been exponentially on the rise. Finding effective treatment has been the core of attention of many scientific reports and antivirals are in the center of those treatments. Numerous antivirals are being studied for the management of the coronavirus disease 2019 (COVID-19) pneumonia caused by the SARS-CoV-2. Remdesivir was the first drug to gain emergency FDA approval to be used in COVID-19. Similarly, favipiravir, an anti-influenza drug, is being studied as a potential agent against COVID-19. Contrastingly, hydroxychloroquine has been a controversial drug in the management of COVID-19. Nevertheless, the National Institute of Health (NIH), along with the World Health Organization (WHO), have discontinued clinical trials for hydroxychloroquine as the drug showed little or no survival benefit. Ivermectin, an antihelminthic drug, has shown antiviral properties previously. Additionally, it was described to be effective in vivo against the SARS-CoV-2. However, its survival benefit in patients with COVID-19 has not been documented. We herein propose the theory of inhaled ivermectin which can attain the desired lung concentration that will render it effective against SARS-CoV-2. SN - 2168-8184 UR - https://www.unboundmedicine.com/medline/citation/33062500/Ivermectin:_A_Closer_Look_at_a_Potential_Remedy_ DB - PRIME DP - Unbound Medicine ER -